Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma

BACKGROUND: Until 2010, stage III or IV malignant melanoma (MM) had a poor prognosis. The discovery of immune checkpoint inhibitors (ICIs) in 2011 changed the treatment landscape. Promising results in patient survival with a checkpoint inhibitor prompted research into combination therapies. In 2016,...

Descripción completa

Detalles Bibliográficos
Autores principales: Özdemir, Dilay, Büssgen, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521452/
https://www.ncbi.nlm.nih.gov/pubmed/37749653
http://dx.doi.org/10.1186/s40545-023-00611-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521452/
https://www.ncbi.nlm.nih.gov/pubmed/37749653
http://dx.doi.org/10.1186/s40545-023-00611-7

Ejemplares similares